NCT04992156已完成不适用
A Retrospective Study of Prediction of 18F-FES-PET/CT Parameters on the Outcome of Palbociclib Combined With Endocrine Therapy in Patients With HR+ and HER2-metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
To investigate parameters based on 18F-FES-PET/CT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HR+/HER2-MBC.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients aged 18-70 years.
- •Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- •HR+ was defined as estrogen receptor- or progesterone receptor-positive status by immunohistochemistry.
- •HER2 status was determined by immunohistochemistry or fluorescence in situ hybridization.
- •Palbociclib treatment of metastatic breast cancer for at least one cycle.
- •Available medical history.
排除标准
- •1.Incomplete medical history.
研究组 & 干预措施
Patients cohort
Patients with MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FES PET/CT before the initiation of Palbociclib was included.
干预措施: Palbociclib (Drug)
结局指标
主要结局
PFS
时间窗: Through study completion, an expected average of 12 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast CancerEstrogen Receptor-positive Breast CancerFulvestrantNCT03768479First Affiliated Hospital Xi'an Jiaotong University68
已完成
不适用
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) ProgressingProstate CancerNCT06460454Central Hospital, Nancy, France100
Unknown
3 期
A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate CancerProstate Cancer RecurrentNCT04734184Curium PET France217
已完成
不适用
Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical CancerCervical CancerNCT04008095University Hospital, Brest40
已完成
不适用
18F-FDG PET Radiomics of Diffuse Large B-cell LymphomaLymphoma, Large B-Cell, DiffuseNCT04317313Second Affiliated Hospital, School of Medicine, Zhejiang University152